Pedroso Ivonne, Garcia Marité, Casabona Enrique, Morales Lilia, Bringas Maria Luisa, Pérez Leslie, Rodríguez Teresita, Sosa Ileana, Ricardo Yordanka, Padrón Arnoldo, Amaro Daniel
International Center for Neurological Restoration, La Habana 11300, Cuba;
The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu 610054, China.
Behav Sci (Basel). 2018 May 21;8(5):51. doi: 10.3390/bs8050051. eCollection 2018 May.
Treatment strategies in Parkinson's disease (PD) can improve a patient's quality of life but cannot stop the progression of PD. We are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of erythropoietin. In Cuba, the Center for Molecular Immunology (CIM) is a cutting edge scientific center where the recombinant form (EPOrh) and recombinant human erythropoietin with low sialic acid (NeuroEPO) are produced. We performed two clinical trials to evaluate the safety and tolerability of these two drugs in PD patients. In this paper we want to show the positive results of the additional cognitive tests employed, as part of the comprehensive assessment. Two studies were conducted in PD patients from the outpatient clinic of CIREN, including = 10 and = 26 patients between 60 and 66 years of age, in stages 1 to 2 of the Hoehn and Yahr Scale. The first study employed recombinant human (rhEPO) and the second an intranasal formulation of neuroEPO. All patients were evaluated with a battery of neuropsychological scales composed to evaluate global cognitive functioning, executive function, and memory. The general results in both studies showed a positive response to the cognitive functions in PD patients, who were undergoing pharmacological treatment with respect to the evaluation ( < 0.05) before the intervention. Erythropoietin has a discrete positive effect on the cognitive functions of patients with Parkinson's disease, which could be interpreted as an effect of the neuroprotective properties of this molecules. To confirm the results another clinical trial phase III with neuroEPO is in progress, also designed to discard any influence of a placebo effect on cognition.
帕金森病（PD）的治疗策略可以改善患者的生活质量，但无法阻止帕金森病的进展。我们正在寻找能够改变疾病自然进程的不同替代方法，最近的研究已经证明了促红细胞生成素的神经保护特性。在古巴，分子免疫学中心（CIM）是一个前沿科学中心，在那里生产重组形式（EPOrh）和低唾液酸重组人促红细胞生成素（NeuroEPO）。我们进行了两项临床试验，以评估这两种药物在帕金森病患者中的安全性和耐受性。在本文中，我们想展示作为综合评估一部分所采用的额外认知测试的积极结果。对来自CIREN门诊的帕金森病患者进行了两项研究，包括10名和26名年龄在60至66岁之间、处于Hoehn和Yahr量表1至2期的患者。第一项研究使用重组人促红细胞生成素（rhEPO），第二项研究使用NeuroEPO的鼻内制剂。所有患者都接受了一系列神经心理学量表的评估，这些量表旨在评估整体认知功能、执行功能和记忆力。两项研究的总体结果显示，正在接受药物治疗的帕金森病患者在干预前的评估基础上，对认知功能有积极反应（P<0.05）。促红细胞生成素对帕金森病患者的认知功能有离散的积极影响，这可以解释为该分子神经保护特性所产生的效果。为了证实这些结果，另一项关于NeuroEPO的III期临床试验正在进行中，该试验也旨在排除安慰剂效应对认知的任何影响。
